HiFiBiO Therapeutics, a multinational biotherapeutics start-up that mobilizes the human immune system to combat disease, announced on Wednesday the completion of a US$67 million series C round of financing led by Boston-born investment company IDG Capital.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
